Skip navigation
Image Alt

Powering Precision

Learn more about our evolving body of data presented at the 2022 ASCO Congress on June 3- 6, 2022.
Contact us for deeper insight into Signatera's personalized, tumor-informed approach.

Scientific presentations to further validate the utility of Signatera in multiple tumor types

  • Breast Cancer: Serial postoperative ctDNA monitoring of breast cancer recurrence

    Ekaterina Kalashnikova, PhD
  • Lung Cancer: Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy.

    Emily Lebow, MD
    Memorial Sloan Kettering Cancer Center
  • Sarcoma: Circulating Tumor DNA (ctDNA) detection of Molecular Residual Disease (MRD) as a Potential Biomarker in localized Soft Tissue Sarcoma (STS)

    Abdulazeez Salawu, PhD
    Princess Margaret Cancer Centre and Mount Sinai Hospital
  • Merkel Cell: Circulating tumor DNA to measure Merkel cell carcinoma tumor burden and detect early recurrence

    Richa Rathore, PhD
  • Metastatic Renal: Monitoring Efficacy of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma using a Personalized and Tumor Informed ctDNA Assay

    Christine B. Peterson, PhD
    Department of Biostatistics, MD Anderson Cancer Center
  • Colon Cancer: A Single-arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who remain ctDNA+ after Curative Surgery and Adjuvant Chemotherapy

    Thomas George, MD
    Director of the GI Oncology Program, University of Florida
  • Colon Cancer: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): NRG-GI008

    N. Arvind Dasari, MD
    Associate Professor Dept of Gastrointestinal Medical Oncology, MD Anderson Cancer Center
  • Immunotherapy: External validation of the VIGex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).

    Alberto Hernando-Calvo
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre

Natera led an Industry Expert Theater on June 5

Natera’s Oncology Portfolio

A single tissue source upfront provides a comprehensive genomic profile

alt text

*Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019

Learn about Signatera for your clinical trial

Well-designed and successful clinical trials help facilitate earlier “go/no go” decision-making. A trial with Signatera can ultimately enhance the R&D pipeline productivity and impact label expansion of approved oncology drugs to new treatment settings.

Why Partner with us?

  • Experienced team with Global reach: CE Mark, three FDA Breakthrough Device Designations, 8 Non-Significant Risk (NSR) determinations

  • >60 Natera IP assets covering ctDNA MRD and monitoring

  • Clinically validated across multiple solid tumors, Signatera has shown to predict relapse in >98% of patients without further treatment*

Learn More


Pan Cancer Brochure
CIRCULATE Japan Sales Aid
How to Order


Immunotherapy Brochure
CRC Brochure
Patient Brochure

Is Signatera right for your patients?

We’re here to help you find out